13F Portfolios

Spruce Street Capital LP: CENTESSA PHARMACEUTICALS PLC (CNTA): Quarterly 13F Position History

As of Q1 2026, Spruce Street Capital LP reported 489,849 shares of CENTESSA PHARMACEUTICALS PLC (CNTA), worth $19.5M and representing 4.7% of its 13F equity book. Quarter-over-quarter share count change: + 411,852 (+528.0%) . The position first appeared in Q4 2025 and has been disclosed across 2 13F-HR filings in Pactolio's tracked window.

Recent initiation: Spruce Street Capital LP first reported CNTA on the Q4 2025 filing — fewer than three quarters of history are available.

Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 2 quarter s

Quarter Shares QoQ Share Change Share Change (%) Market Value Weight Implied Price
Q1 2026 489,849 +411,852 +528.0% $19.5M 4.7% $39.7
Q4 2025 77,997 $2.0M 0.6% $25.0

Methodology & FAQ

How This Position History Is Sourced

Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.

When did Spruce Street Capital LP first disclose a CNTA position in 13F-HR filings?

Spruce Street Capital LP first reported CENTESSA PHARMACEUTICALS PLC (CNTA) on its 13F-HR filing for the period ending 2025-12-31 (Q4 2025). The position has appeared on 2 reported quarters within Pactolio's tracked window.

What was Spruce Street Capital LP's most recent quarter-over-quarter share-count change in CNTA?

Between Q4 2025 and Q1 2026, Spruce Street Capital LP added 411,852 shares of CNTA (+528.0%), bringing the total reported position to 489,849 shares at a market value of $19.5M.

Does the implied price-per-share represent Spruce Street Capital LP's cost basis in CNTA?

No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.